ClinicalTrials.gg
RecruitingNCT07781553Updated Aug 24, 2026

Biomarkers to Predict Rotator Cuff Repair Healing on Postoperative MRI

An interventional study of MRN in Rotator Cuff Tears, sponsored by Joseph W. Galvin. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Joseph W. Galvin · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 168 studies in Rotator Cuff Injuries with a site in United States — 40 open to participants now, 50 under way, none of them phase 3. Rotator Cuff Injuries · United States.

Planned enrollment
62nd of 130
60 · median 60
Started
2026
with 4 others
No phase
86 of 168
21 open now
Primary completion
2027-07
later than 32 of 49 live
Registered
166th of 168
by date

Among the 168 studies in Rotator Cuff Injuries with a site in United States, this one is the 62nd largest by planned enrollment of the 130 interventional ones, is one of 5 that started in 2026, is one of 86 with no phase, reaches primary completion later than 32 of the 49 other live ones, and was the 166th registered.

By phase

168 studies; the count open now beside each. This study's row is marked.

No phasethis study86 · 21 open
Observational38 · 10 open
Phase 422 · 4 open
Phase 18 · 1 open
Phase 26 · 2 open
Phase 1/23 · 2 open
Phase 33 · 0 open
Phase 2/32 · 0 open

By the year they started

First in 2005; this study’s year is marked. 5 started in 2026.

Size and results

Median enrollment 60 across the 130 interventional studies, 77 across the 38 observational. Of the 86 that completed or were terminated, 28 (33%) have results posted.

Was this useful?
Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 168 studies in Rotator Cuff Injuries with a site in United States, or all of them as a file.
02

Study summary

Rotator cuff repair healing is highly variable with healing failure rates ranging from 11 to 94%. To this date, there are no specific biomarkers in shoulder tissues that can be associated with rotator cuff healing after surgery. The purpose of this study is to perform diagnostic imaging study (MRI without contrast), for research purposes, to subjects in the Orthopedics Biobank (IRB#202403832), to identify biomarkers associated with failure of rotator cuff repair healing. We will evaluate biomarkers in synovial fluid and shoulder tissues collected and analyzed as part of the IRB#202403832, and correlate the difference in biomarkers in patients that did and did not have signs of healing in the MRI. Secondarily, we aim to develop a model using demographics, radiographic parameters/MRI measurements and biomarkers to accurately predict rotator cuff repair healing rates at 1-year following surgery.

This will be a study from a population of patients who are enrolled in the Orthopedic biorepository under IRB #202403832.

Patients who underwent a rotator cuff repair will be invited to get an MRI without contrast of their operated shoulder at a period between 6 months to 1 year post-operative.

Read the detailed description

Rotator cuff repair healing is highly variable with healing failure rates ranging from 11 to 94% [11-15]. A number of variables have been identified which influence rotator cuff repair healing rates including: older age (> 70 years old), size of the tear in anterior posterior dimension, level of tendon retraction, muscle quality and fatty infiltration, osteoporosis, smoking, family history of rotator cuff tears, diagnosis of diabetes mellitus, and level of work activity [7,16-26]. However, there is a paucity of literature and investigation into biomarkers significantly associated with rotator cuff repair healing rates. Tashjian et al. investigated 72 patients undergoing arthroscopic rotator cuff repair for a full-thickness posterosuperior tear. Magnetic resonance imaging studies were performed at a minimum of 1 year postoperatively. The authors found that 42% of repairs failed to heal. Multivariate regression analysis showed a significant association between a family history of rotator cuff tears and overall healing failure (P = .036). Additionally, they identified an increased risk for the presence of a rare allele for SNP rs17583842 single-nucleotide polymorphism (SNP) in the estrogen-related receptor beta (ESRRB) gene. This is the first genetic biomarker to be identified as significantly associated with repair healing. Additional authors have evaluated transcriptomics and gene expression differences in rotator cuff tissue collected during surgery between patients who had good outcomes versus those who had a retear. They found that patients who had poor healing outcomes showed greater expression of gene sets related to extracellular matrix production (P \< .0001) and cellular biosynthetic pathways (P \< .001), while patients who had good healing outcomes showed greater expression of genes associated with the proinflammatory (M1) macrophage phenotype (P \< .05). Although this data is interesting, tissue level biomarkers are less useful in the clinical setting as a preoperative prognostic tool. No studies to our knowledge have identified blood transcriptomic or proteomic biomarkers associated with rotator cuff tear healing.

Therefore, we aim to investigate this through this protocol. Numerous studies have identified that the diagnosis of diabetes mellitus type 2 (DM2) is a risk factor for failure of rotator cuff repair healing [28]. Yang et al. conducted a meta-analysis to compare clinical outcomes and retear rates after rotator cuff repair in patients with and without diabetes. Diabetes was associated with a higher retear rate (19.3% in patients without diabetes vs 28.2% in patients with diabetes; P \< .0001). The retear rate according to the severity of sustained hyperglycemia in the subgroup analysis was 14.6% in patients without diabetes, versus 22.7% in patients with well-controlled diabetes (\<7.0% of preoperative serum HbA1c level; P = .12) and 40% in patients with uncontrolled diabetes (HbA1c level >7.0%; P \< .00001). Recently, studies have identified that serum fructosamine, rather than Hemoglobin A1C percentage, is a more accurate marker of acute glycemic control. Shohat et al. evaluated 1119 patients undergoing total knee arthroplasty. They found that patients with high fructosamine (> 293) were 11.2 times more likely to develop prosthetic joint infection compared with patients with low fructosamine (p = 0.001). Another study published in the prestigious Nature Journal by Shohat et al. assessed the utility of serum fructosamine to predict adverse outcomes following total hip arthroplasty (THA) [30]. Patients with elevated fructosamine were also associated with more readmissions (16.7% vs. 4.4%, p \< 0.007) and a higher mortality rate (3.7% vs. 0.6%, p = 0.057). We hypothesize that fructosamine level is significantly associated with healing rates following rotator cuff repair and plan to investigate this in a prospective fashion through this protocol.

One of the aims of this study protocol is to develop a model using demographics, radiographic parameters/MRI measurements and biomarkers to accurately predict rotator cuff repair healing rates at 1-year following surgery. Kwon et al. conducted a case-control study of 603 patients who underwent arthroscopic rotator cuff repair and had 1-year follow up with a postoperative MRI. Of the 603 patients, the healing rate was 24%. The following independent risk factors were identified in the multivariate analysis: age > 70 years at the time of surgery (P = .003, Odds Ratio (OR) = 2.71), size of the tear in anterior posterior dimension (P = .033, OR = 1.94), level of tendon retraction (P = .000, OR = 4.56), fatty infiltration of infraspinatus exceeding grade 2 (P = .001, OR = 2.91), low bone mineral density as measured on DEXA scans (T score > -2.5, P = .04, OR = 1.95), and high level of work activity (P = .036, OR = 2.18). They created a 15-point scoring system comprised the following: 4 points for retraction; 3 points for fatty infiltration of infraspinatus; and 2 points for anteroposterior tear size, age, bone mineral density, and work activity. These variables were weighted according to multivariate analysis ORs. Patients with less than or equal to 4 points had a 6.0% healing failure rate, and those with greater than or equal to 5 and greater than or equal to 10 points had 55.2% and 86.2% healing failure rates, respectively. This Rotator Cuff Healing Index (ROHI) score is clinically helpful as it can provide preoperative prognostic information to the surgeon and patient to guide decision making on whether to perform an arthroscopic repair, perform a repair with possible patch augmentation, or potentially guide the decision making to a reverse shoulder arthroplasty. Through this study protocol, we aim to identify current accepted protein biomarkers (fructosamine) and perform discovery proteomics and transcriptomics to identify novel biomarkers associated with rotator cuff repair healing.

03

Conditions studied

  • Rotator Cuff Tears

Browse trials for

Keywords

  • rotator cuff tear; rotator cuff healing
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

age 18-99 years partial or full thickness posterior superior rotator cuff tear that underwent surgical repair and are consented in the Orthopedics Biobank under IRB# 202403832.

Exclusion criteria prisoners pregnant patients patients with prior shoulder surgery on the ipsilateral side adhesive capsulitis patients undergoing concomitant distal clavicle resection worker's compensation patients with postoperative complications.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Rotator cuff repair

    All participants of the Orthopedics Biobank who underwent a rotator cuff repair will be part of arm 1

    Diagnostic Test: MRN

Interventions

  • Diagnostic testMRN

    MRN without contrast

06

What researchers measure

Primary outcomes

  1. Rotator cuff healing

    Rotator cuff healing postoperatively, as assessed on MRI

    Time frame: 6 months to 1 year post-operative

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jul 2027, 10 months later.

Of 228 non-industry interventional studies with no phase under Rotator Cuff Injuries, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 10 months is below that.

Counting every sponsor, half of 252 studies reached it within 23 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2026
First posted
Aug 24, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Jul 30, 2027
CompletionEst.
Aug 30, 2027
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07781553
Lead sponsor
Joseph W. Galvin
Responsible party
Joseph W. Galvin (Assistant Professor, University of Iowa) — Sponsor-investigator
First posted
Aug 24, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Jul 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Aug 24, 2026

Study contacts

Joseph Galvin, Other, MD
Contact
joseph-galvin@uiowa.edu
3193848378
Maria F Bozoghlian, MD
Contact
maria-bozoghlian@uiowa.edu
3196785003
Joseph Galvin, MD
principal investigator · University of Iowa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion